OGN — Organon & Co.
$13.81+0.22%
Last close: · regular session
Last 60 sessions
OGN closed at $13.81 (+0.22%) on Oct 29, 2026. Float: 261.5M shares. Latest SEC filing: 10-Q on Oct 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for OGN in the TickerWise workspace.
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 10,000
- Website: https://www.organon.com
Latest SEC filings for OGN
Latest OGN news
- Organon declares $0.02 dividend Read article
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Read article
- Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Read article
- Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock Read article
- Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.